Gout Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents), By Disease Condition, By Distribution Channel (Hospital Pharmacy), By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 3 Business Days
Gout Therapeutics Market Growth & Trends
The global gout therapeutics market size is anticipated to reach USD 4.13 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 6.45% from 2025 to 2030. The growth of the market is attributed to the global rise in disease burden, initiatives undertaken by government and private organizations to spread awareness among people, and the recent development of novel therapies in the space. Furthermore, the growing number of clinical pipeline drugs offers lucrative market growth opportunities.
The world is witnessing an increasing prevalence of gout, which is the key factor driving market growth. For instance, according to an Elsevier article, in 2021, Australia reported prevalence rates between 1.5% to 2.9% for gout. Similarly, in 2021, Canada and UK reported approximately 4% and 2.33% rise in disease cases respectively. High prevalence is further supported by the high geriatric population, improper diets such as consumption of alcohol and fructose, increasing sedentary lifestyle, and comorbidities like renal impairment, cardiovascular diseases, and diabetes.
The robust clinical trial pipeline and the anticipated launch of new therapeutics are expected to boost market growth over the forecast period. Presently, drug candidates like Jiangsu HengRui Medicine Co., Ltd.’s SHR4640 are in phase 3 clinical investigation for the treatment of gout. Similarly, in March 2023, Selecta Biosciences, Inc announced positive results for the Phase 3 DISSOLVE I & II placebo-controlled randomized clinical trials of SEL-212. SEL-212 is indicated for chronic refractory gout.
Key players are undertaking strategic initiatives such as collaborations, mergers and acquisitions, agreements, and financial investments, driving market growth. For instance, in June 2021, Horizon Therapeutics plc collaborated with Arrowhead Pharmaceuticals to develop RNAi therapeutic, a potential treatment for uncontrolled gout. In July 2022, the company received expanded FDA approval for Krystexxa for patients with uncontrolled gout. It is used in combination with immunotherapy and chemotherapy drug, methotrexate.
Additionally, in March 2023, Horizon organized a campaign, “Weed it G'out” for National Kidney Month. The campaign uses flowers and weeds to depict the correlation to the effect of uric acid on kidneys. The campaign aims to create awareness and urge people to take gout seriously and consult a specialist.
Gout Therapeutics Market Report Highlights
Takeda Pharmaceutical Company Limited
Novartis AG
Regeneron Pharmaceuticals Inc.
AstraZeneca
Arrowhead Pharmaceuticals, Inc.
Merck & Co., Inc.
Teijin Pharma Ltd.
GSK plc.
Zydus Group
Gout Therapeutics Market Growth & Trends
The global gout therapeutics market size is anticipated to reach USD 4.13 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 6.45% from 2025 to 2030. The growth of the market is attributed to the global rise in disease burden, initiatives undertaken by government and private organizations to spread awareness among people, and the recent development of novel therapies in the space. Furthermore, the growing number of clinical pipeline drugs offers lucrative market growth opportunities.
The world is witnessing an increasing prevalence of gout, which is the key factor driving market growth. For instance, according to an Elsevier article, in 2021, Australia reported prevalence rates between 1.5% to 2.9% for gout. Similarly, in 2021, Canada and UK reported approximately 4% and 2.33% rise in disease cases respectively. High prevalence is further supported by the high geriatric population, improper diets such as consumption of alcohol and fructose, increasing sedentary lifestyle, and comorbidities like renal impairment, cardiovascular diseases, and diabetes.
The robust clinical trial pipeline and the anticipated launch of new therapeutics are expected to boost market growth over the forecast period. Presently, drug candidates like Jiangsu HengRui Medicine Co., Ltd.’s SHR4640 are in phase 3 clinical investigation for the treatment of gout. Similarly, in March 2023, Selecta Biosciences, Inc announced positive results for the Phase 3 DISSOLVE I & II placebo-controlled randomized clinical trials of SEL-212. SEL-212 is indicated for chronic refractory gout.
Key players are undertaking strategic initiatives such as collaborations, mergers and acquisitions, agreements, and financial investments, driving market growth. For instance, in June 2021, Horizon Therapeutics plc collaborated with Arrowhead Pharmaceuticals to develop RNAi therapeutic, a potential treatment for uncontrolled gout. In July 2022, the company received expanded FDA approval for Krystexxa for patients with uncontrolled gout. It is used in combination with immunotherapy and chemotherapy drug, methotrexate.
Additionally, in March 2023, Horizon organized a campaign, “Weed it G'out” for National Kidney Month. The campaign uses flowers and weeds to depict the correlation to the effect of uric acid on kidneys. The campaign aims to create awareness and urge people to take gout seriously and consult a specialist.
Gout Therapeutics Market Report Highlights
- NSAIDs segment accounted for the largest share of the market in 2024 due to the high prescription rate, low cost, and strong presence in the market.
- Based on disease condition, the acute condition segment held 65.77% of the total market share in 2024, owing to a high patient pool compared to the chronic condition
- In 2024, retail pharmacy held the highest segment share in the space. However, online pharmacy is expected to be the fastest-growing segment over the forecast period
- North America dominated the global market in 2024 owing to factors such as increased gout cases, high awareness among individuals for disease treatment, and better healthcare access in the region
Takeda Pharmaceutical Company Limited
Novartis AG
Regeneron Pharmaceuticals Inc.
AstraZeneca
Arrowhead Pharmaceuticals, Inc.
Merck & Co., Inc.
Teijin Pharma Ltd.
GSK plc.
Zydus Group
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Disease Condition
1.2.3. Distribution Channel
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug Class outlook
2.2.2. Disease Condition outlook
2.2.3. Distribution Channel outlook
2.2.4. Regional outlook
2.3. Competitive Insights
CHAPTER 3. GOUT THERAPEUTICS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Gout Therapeutics Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
3.3.4. Pipeline Analysis
3.3.4.1. Phase 1
3.3.4.2. Phase 2
3.3.4.3. Phase 2
CHAPTER 4. GOUT THERAPEUTICS MARKET: DRUG CLASS ESTIMATES & TREND ANALYSIS
4.1. Global Gout Therapeutics Market: Drug Class Dashboard
4.2. Global Gout Therapeutics Market: Drug Class Movement Analysis
4.3. Global Gout Therapeutics Market by Drug Class, Revenue
4.4. NSAIDs
4.4.1. NSAIDs market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Corticosteroids
4.5.1. Corticosteroids market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Colchicine
4.6.1. Colchicine market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Urate-Lowering Agents
4.7.1. Urate-Lowering Agents market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Others
4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. GOUT THERAPEUTICS MARKET: DISEASE CONDITION ESTIMATES & TREND ANALYSIS
5.1. Global Gout Therapeutics Market: Disease Condition Dashboard
5.2. Global Gout Therapeutics Market: Disease Condition Movement Analysis
5.3. Global Gout Therapeutics Market by Disease Condition, Revenue
5.4. Acute Gout
5.4.1. Acute Gout market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Chronic Gout
5.6. Chronic Gout market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. GOUT THERAPEUTICS MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS
6.1. Global Gout Therapeutics Market: Distribution Channel Dashboard
6.2. Global Gout Therapeutics Market: Distribution Channel Movement Analysis
6.3. Global Gout Therapeutics Market by Distribution Channel, Revenue
6.4. Hospital Pharmacy
6.4.1. Hospital Pharmacy market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Retail Pharmacy
6.5.1. Retail Pharmacy market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Online Pharmacy
6.6.1. Online Pharmacy market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. GOUT THERAPEUTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY DRUG CLASS, DISEASE CONDITION, AND DISTRIBUTION CHANNEL.
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2024
8.3.4. Takeda Pharmaceutical Company Limited
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Novartis Pharmaceuticals Corporation
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Regeneron Pharmaceuticals Inc.
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Merck & Co., Inc.
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. AstraZeneca
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Arrowhead Pharmaceuticals Inc.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. AstraZeneca
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Teijin Pharma Ltd.
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. GSK plc.
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. Zydus Group
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Disease Condition
1.2.3. Distribution Channel
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug Class outlook
2.2.2. Disease Condition outlook
2.2.3. Distribution Channel outlook
2.2.4. Regional outlook
2.3. Competitive Insights
CHAPTER 3. GOUT THERAPEUTICS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Gout Therapeutics Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
3.3.4. Pipeline Analysis
3.3.4.1. Phase 1
3.3.4.2. Phase 2
3.3.4.3. Phase 2
CHAPTER 4. GOUT THERAPEUTICS MARKET: DRUG CLASS ESTIMATES & TREND ANALYSIS
4.1. Global Gout Therapeutics Market: Drug Class Dashboard
4.2. Global Gout Therapeutics Market: Drug Class Movement Analysis
4.3. Global Gout Therapeutics Market by Drug Class, Revenue
4.4. NSAIDs
4.4.1. NSAIDs market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Corticosteroids
4.5.1. Corticosteroids market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Colchicine
4.6.1. Colchicine market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Urate-Lowering Agents
4.7.1. Urate-Lowering Agents market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Others
4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. GOUT THERAPEUTICS MARKET: DISEASE CONDITION ESTIMATES & TREND ANALYSIS
5.1. Global Gout Therapeutics Market: Disease Condition Dashboard
5.2. Global Gout Therapeutics Market: Disease Condition Movement Analysis
5.3. Global Gout Therapeutics Market by Disease Condition, Revenue
5.4. Acute Gout
5.4.1. Acute Gout market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Chronic Gout
5.6. Chronic Gout market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. GOUT THERAPEUTICS MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS
6.1. Global Gout Therapeutics Market: Distribution Channel Dashboard
6.2. Global Gout Therapeutics Market: Distribution Channel Movement Analysis
6.3. Global Gout Therapeutics Market by Distribution Channel, Revenue
6.4. Hospital Pharmacy
6.4.1. Hospital Pharmacy market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Retail Pharmacy
6.5.1. Retail Pharmacy market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Online Pharmacy
6.6.1. Online Pharmacy market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. GOUT THERAPEUTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY DRUG CLASS, DISEASE CONDITION, AND DISTRIBUTION CHANNEL.
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2024
8.3.4. Takeda Pharmaceutical Company Limited
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Novartis Pharmaceuticals Corporation
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Regeneron Pharmaceuticals Inc.
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Merck & Co., Inc.
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. AstraZeneca
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Arrowhead Pharmaceuticals Inc.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. AstraZeneca
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Teijin Pharma Ltd.
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. GSK plc.
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. Zydus Group
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
LIST OF TABLES
Table 1 List of abbreviation
Table 2 North America Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 3 North America Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 4 North America Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 5 U.S. Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 6 U.S. Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 7 U.S. Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 8 Canada Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 9 Canada Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 10 Canada Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 11 Mexico Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 12 Mexico Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 13 Mexico Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 14 Europe Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 15 Europe Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 16 Europe Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 17 Germany Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 18 Germany Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 19 Germany Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 20 UK Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 21 UK Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 22 UK Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 23 France Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 24 France Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 25 France Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 26 Italy Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 27 Italy Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 28 Italy Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 29 Spain Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 30 Spain Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 31 Spain Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 32 Denmark Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 33 Denmark Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 34 Denmark Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 35 Sweden Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 36 Sweden Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 37 Sweden Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 38 Norway Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 39 Norway Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 40 Norway Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 41 Asia Pacific Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 42 Asia Pacific Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 43 Asia Pacific Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 44 China Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 45 China Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 46 China Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 47 Japan Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 48 Japan Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 49 Japan Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 50 India Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 51 India Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 52 India Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 53 South Korea Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 54 South Korea Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 55 South Korea Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 56 Australia Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 57 Australia Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 58 Australia Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 59 Thailand Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 60 Thailand Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 61 Thailand Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 62 Latin America Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 63 Latin America Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 64 Latin America Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 65 Brazil Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 66 Brazil Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 67 Brazil Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 68 Argentina Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 69 Argentina Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 70 Argentina Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 71 MEA Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 72 MEA Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 73 MEA Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 74 South Africa Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 75 South Africa Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 76 South Africa Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 77 Saudi Arabia Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 78 Saudi Arabia Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 79 Saudi Arabia Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 80 UAE Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 81 UAE Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 82 UAE Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 83 Kuwait Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 84 Kuwait Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 85 Kuwait Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 1 List of abbreviation
Table 2 North America Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 3 North America Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 4 North America Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 5 U.S. Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 6 U.S. Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 7 U.S. Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 8 Canada Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 9 Canada Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 10 Canada Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 11 Mexico Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 12 Mexico Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 13 Mexico Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 14 Europe Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 15 Europe Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 16 Europe Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 17 Germany Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 18 Germany Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 19 Germany Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 20 UK Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 21 UK Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 22 UK Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 23 France Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 24 France Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 25 France Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 26 Italy Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 27 Italy Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 28 Italy Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 29 Spain Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 30 Spain Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 31 Spain Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 32 Denmark Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 33 Denmark Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 34 Denmark Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 35 Sweden Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 36 Sweden Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 37 Sweden Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 38 Norway Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 39 Norway Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 40 Norway Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 41 Asia Pacific Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 42 Asia Pacific Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 43 Asia Pacific Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 44 China Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 45 China Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 46 China Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 47 Japan Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 48 Japan Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 49 Japan Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 50 India Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 51 India Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 52 India Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 53 South Korea Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 54 South Korea Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 55 South Korea Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 56 Australia Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 57 Australia Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 58 Australia Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 59 Thailand Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 60 Thailand Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 61 Thailand Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 62 Latin America Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 63 Latin America Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 64 Latin America Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 65 Brazil Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 66 Brazil Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 67 Brazil Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 68 Argentina Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 69 Argentina Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 70 Argentina Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 71 MEA Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 72 MEA Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 73 MEA Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 74 South Africa Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 75 South Africa Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 76 South Africa Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 77 Saudi Arabia Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 78 Saudi Arabia Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 79 Saudi Arabia Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 80 UAE Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 81 UAE Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 82 UAE Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 83 Kuwait Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 84 Kuwait Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
Table 85 Kuwait Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Gout Therapeutics market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Product and Distribution Channel segment snapshot
Fig. 10 Application segment snapshot
Fig. 11 Competitive landscape snapshot
Fig. 12 Pharmaceutical market (USD Billion)
Fig. 13 Market dynamics
Fig. 14 Porter’s five forces analysis
Fig. 15 PESTLE analysis
Fig. 16 Gout Therapeutics market: Drug Class outlook and key takeaways
Fig. 17 Gout Therapeutics market: Drug Class movement analysis
Fig. 18 Gout Therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 NSAIDs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Corticosteroids market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Colchicine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Urate-Lowering Agents market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Gout Therapeutics market: Disease Condition outlook and key takeaways
Fig. 25 Gout Therapeutics market: Disease Condition movement analysis
Fig. 26 Acute Gout market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Chronic Gout market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Gout Therapeutics market: Distribution Channel and key takeaways
Fig. 29 Gout Therapeutics market: Distribution Channel movement analysis
Fig. 30 Hospital Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Retail Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Online Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Gout Therapeutics market revenue, by region, 2024 & 2030, (USD million)
Fig. 34 Regional marketplace: Key takeaways
Fig. 35 North America gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Key country dynamics
Fig. 37 Target disease prevalence
Fig. 38 U.S. gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Key country dynamics
Fig. 40 Target disease prevalence
Fig. 41 Canada gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Key country dynamics
Fig. 43 Target disease prevalence
Fig. 44 Mexico gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Key country dynamics
Fig. 46 Target disease prevalence
Fig. 47 Europe gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Key country dynamics
Fig. 49 Target disease prevalence
Fig. 50 UK gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Key country dynamics
Fig. 52 Target disease prevalence
Fig. 53 Germany gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Key country dynamics
Fig. 55 Target disease prevalence
Fig. 56 France gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Key country dynamics
Fig. 58 Target disease prevalence
Fig. 59 Spain gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Key country dynamics
Fig. 61 Target disease prevalence
Fig. 62 Italy gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Key country dynamics
Fig. 64 Target disease prevalence
Fig. 65 Denmark gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Key country dynamics
Fig. 67 Target disease prevalence
Fig. 68 Sweden gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 Key country dynamics
Fig. 70 Target disease prevalence
Fig. 71 Norway gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 Rest of Europe gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Asia Pacific gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 74 Key country dynamics
Fig. 75 Target disease prevalence
Fig. 76 Japan gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Key country dynamics
Fig. 78 Target disease prevalence
Fig. 79 China gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 Key country dynamics
Fig. 81 Target disease prevalence
Fig. 82 India gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 Key country dynamics
Fig. 84 Target disease prevalence
Fig. 85 Australia gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 Key country dynamics
Fig. 87 Thailand gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 88 Key country dynamics
Fig. 89 South Korea gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 90 Rest of Asia Pacific gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 91 Latin America gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 92 Key country dynamics
Fig. 93 Target disease prevalence
Fig. 94 Brazil gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 95 Key country dynamics
Fig. 96 Target disease prevalence
Fig. 97 Argentina gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 98 Rest of Latin America gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 99 MEA gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 100 Key country dynamics
Fig. 101 Target disease prevalence
Fig. 102 South Africa gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 103 Key country dynamics
Fig. 104 Target disease prevalence
Fig. 105 Saudi Arabia gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 106 Key country dynamics
Fig. 107 Target disease prevalence
Fig. 108 UAE gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 109 Key country dynamics
Fig. 110 Target disease prevalence
Fig. 111 Kuwait gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 112 Rest of MEA gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 1 Gout Therapeutics market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Product and Distribution Channel segment snapshot
Fig. 10 Application segment snapshot
Fig. 11 Competitive landscape snapshot
Fig. 12 Pharmaceutical market (USD Billion)
Fig. 13 Market dynamics
Fig. 14 Porter’s five forces analysis
Fig. 15 PESTLE analysis
Fig. 16 Gout Therapeutics market: Drug Class outlook and key takeaways
Fig. 17 Gout Therapeutics market: Drug Class movement analysis
Fig. 18 Gout Therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 NSAIDs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Corticosteroids market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Colchicine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Urate-Lowering Agents market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Gout Therapeutics market: Disease Condition outlook and key takeaways
Fig. 25 Gout Therapeutics market: Disease Condition movement analysis
Fig. 26 Acute Gout market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Chronic Gout market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Gout Therapeutics market: Distribution Channel and key takeaways
Fig. 29 Gout Therapeutics market: Distribution Channel movement analysis
Fig. 30 Hospital Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Retail Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Online Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Gout Therapeutics market revenue, by region, 2024 & 2030, (USD million)
Fig. 34 Regional marketplace: Key takeaways
Fig. 35 North America gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Key country dynamics
Fig. 37 Target disease prevalence
Fig. 38 U.S. gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Key country dynamics
Fig. 40 Target disease prevalence
Fig. 41 Canada gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Key country dynamics
Fig. 43 Target disease prevalence
Fig. 44 Mexico gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Key country dynamics
Fig. 46 Target disease prevalence
Fig. 47 Europe gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Key country dynamics
Fig. 49 Target disease prevalence
Fig. 50 UK gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Key country dynamics
Fig. 52 Target disease prevalence
Fig. 53 Germany gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Key country dynamics
Fig. 55 Target disease prevalence
Fig. 56 France gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Key country dynamics
Fig. 58 Target disease prevalence
Fig. 59 Spain gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Key country dynamics
Fig. 61 Target disease prevalence
Fig. 62 Italy gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Key country dynamics
Fig. 64 Target disease prevalence
Fig. 65 Denmark gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Key country dynamics
Fig. 67 Target disease prevalence
Fig. 68 Sweden gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 Key country dynamics
Fig. 70 Target disease prevalence
Fig. 71 Norway gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 Rest of Europe gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Asia Pacific gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 74 Key country dynamics
Fig. 75 Target disease prevalence
Fig. 76 Japan gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Key country dynamics
Fig. 78 Target disease prevalence
Fig. 79 China gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 Key country dynamics
Fig. 81 Target disease prevalence
Fig. 82 India gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 Key country dynamics
Fig. 84 Target disease prevalence
Fig. 85 Australia gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 Key country dynamics
Fig. 87 Thailand gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 88 Key country dynamics
Fig. 89 South Korea gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 90 Rest of Asia Pacific gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 91 Latin America gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 92 Key country dynamics
Fig. 93 Target disease prevalence
Fig. 94 Brazil gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 95 Key country dynamics
Fig. 96 Target disease prevalence
Fig. 97 Argentina gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 98 Rest of Latin America gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 99 MEA gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 100 Key country dynamics
Fig. 101 Target disease prevalence
Fig. 102 South Africa gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 103 Key country dynamics
Fig. 104 Target disease prevalence
Fig. 105 Saudi Arabia gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 106 Key country dynamics
Fig. 107 Target disease prevalence
Fig. 108 UAE gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 109 Key country dynamics
Fig. 110 Target disease prevalence
Fig. 111 Kuwait gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 112 Rest of MEA gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
